Reversing the Trend? The Possibility that Rule Changes May Lead to Fewer Reverse Payments in Pharma Settlements
Anne Layne-Farrar, Nov 01, 2009
This article begins by laying out a simple framework that makes obvious the incentives at play in generic drug entry, brand challenges, and settlements between the two. Once this common understanding has been established, several rule changes that have taken place are summarized one in the form of an amendment to Hatch-Waxman and another in a recent decision by the Court of Appeals for the Federal Circuit. These institutional changes may have the consequence of reducing the prevalence of reverse payments. This possibility suggests a different policy tact might be called for, one that shifts emphasis from determining whether or not reverse payments should be per se illegal to working with the incentives that firms already face and exploiting those incentives to reduce firms inclinations to enter into anticompetitive reverse-payment settlements.
Links to Full Content
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI